Docetaxel Nanoparticle CPC634 in Phase 2 Trial for Platinum-resistant OC

Docetaxel Nanoparticle CPC634 in Phase 2 Trial for Platinum-resistant OC
Cristal Therapeutics has begun patient dosing in its Phase 2a trial evaluating CPC634 — the chemotherapy docetaxel, delivered in nanoparticles — in patients whose ovarian cancer has become resistant to platinum-based chemotherapy. The exploratory study (2018-002117-36) is expected to include 27 patients across 10 clinical sites in the United Kingdom, Belgium, Netherlands, and Spain. Eligible participants received a

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *